Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
  1. IsoPet®
  2. Our IsoPet® Mission

Our Mission. What you and your pet can expect from IsoPet® Therapy.

Message from Mike Korenko Sc.D • CEO | President – Vivos Inc.

Moose - Cancer Survivor. Treated October 2018
Moose - Cancer Survivor. Treated October 2018

Hello to all our followers and supporters.

 

We were very pleased to hear that our first canine sarcoma patient Moose has been 4 years cancer free after IsoPet® Therapy. This is an excellent outcome for Moose, and a strong indicator of the effectiveness of IsoPet® Therapy.

 

However, I am concerned, with an abundance of caution, that the news regarding a single patient does not always provide a complete and balanced picture. We've worked hard to earn a reputation for complete transparency, and do not want to give the incorrect perception that we communicate only the most positive results. We've learned numerous things in our ongoing research and development with this revolutionary product.

 

Information in the medical literature indicates that soft tissue sarcomas are prone to recurrence. Moose had a successful treatment with no indication of recurrence. However, two other patients had secondary tumors that required additional therapy.

 

Another patient had a very large half-pound tumor. IsoPet® therapy effectively killed the tumor, but the small dog’s immune system struggled to absorb such a large mass and it became infected. The recommendation was to surgically remove it so the animal could fully heal. Months later, Bailey lost her fight.

 

In all these cases Isopet® therapy effectively killed the primary tumor thereby increasing the life expectancy and quality of life of the animal. We learned that a combination of surgical removal, either before or after IsoPet® therapy, may be needed to effectively treat very large tumors. We also learned that for sarcomas, more aggressive treatment of the tumor margins may be needed to reduce the probability of recurrence. 

Dr. Darrell Fisher, Dr. Mike Korenko and Dr. Michelle Meyer in the animal clinic where the first treatment of IsoPet took place. (photo: Emily McCarty)
Dr. Darrell Fisher, Dr. Mike Korenko and Dr. Michelle Meyer in the animal clinic where the first treatment of IsoPet took place. (photo: Emily McCarty)

We have been clear that the commercial treatment currently available at Vista Veterinary Hospital and additional licensed regional clinics is considered developmental.
 

We have compelling evidence that IsoPet® will kill the primary tumors in a single same day therapy with very high therapeutic dose and minimal collateral damage. Each tumor type has a different probability of recurrence and we will continue to gain experience as different tumor types are treated. IsoPet® is an important tool in the toolbox of veterinary medicine. It will complement other tools being used, and it definitely will improve and extend the life of many animals.

 

Thank you for your understanding and support of our ongoing Mission. 

 

Michael Korenko Sc. D • CEO | President, Vivos Inc.

Vivos, Inc.

Precision Radionuclide Therapy (PRnT)

OTCQB: RDGL

contact: info@radiogel.com


Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB: RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

RadioGel™ Logo

Precision Radionuclide Therapy (PRnT)

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Regional Clinics
  • IsoPet® Therapy Pets
  • Veterinarians
  • Animal Studies
  • Our IsoPet® Mission
  • Scroll to top